Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 310-315

  Takahashi, Daiei ^a   Nagahama, Kiyotaka ^b   Tsuura, Yukio ^c   Tanaka, Hiroyuki ^c   Tamura, Teiichi ^c  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

Proteinuria; Sunitinib; VEGF

Indexed keywords

ALBUMIN; CREATININE; FUROSEMIDE; SUNITINIB; VASCULOTROPIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DETERIORATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENDOTHELIUM INJURY; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL STROMAL TUMOR; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LABORATORY TEST; LONG TERM CARE; MALE; NEPHROTIC SYNDROME; OCCULT BLOOD; PERITONEUM METASTASIS; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA; RETREATMENT; STOMACH CANCER; WEIGHT GAIN;

AGED; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY; MALE; NEPHROTIC SYNDROME; PROTEINURIA; PYRROLES;

EID: 84863723279     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0543-9     Document Type: Article

References (18)

1. Rock EP, Goodman V, Jiang JX, et al. Food and drug administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107-13.
2. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial. Lancet. 2006;368:1329-38.
3. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358: 1129-36.
4. Bollée G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transpl. 2009;24:682-5.
5. Winn SK, Ellis S, Savage P, Sampson S, March JE. Biopsyproven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: A class effect? Nephrol Dial Transpl. 2009;24:673-5.
6. Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transpl. 2010;25: 1001-3.
7. Rolleman EJ, Weening J, Betjes MGH. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transpl. 2009;24:2002-3.
8. Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol. 2009;2:172-6.
9. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-92.
10. Wu S, Kim C, Bear L, Zhu X, et al. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-9.
11. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49:e23-9.
12. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signaling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46:439-48.
13. Gurevich F, Perazella MA. Renal effects of anti-Angiogenesis therapy: update for the internist. Am J Med. 2009;122:322-8.
14. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM, et al. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56:1168-74.
15. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58.
16. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
17. Kappers MHW, Smedts FMM, Horn T, et al. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295-302.
18. Overkleeft ENM, Goldschmeding R, van Reekum F, Voest EE, Verheul HMW. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21:184-5.